

Development of Candidate Antibody to Block Resistin for Treatment of Inflammatory Bowel Disease

KIM CELL&GENE



NEO GENE PHARM
New Generation Products for Health

IMMUNOLOGY	Candidate
Product Type	Antibody
Indication	IBD
Target	RESISTIN
MoA(Mechanism of Action)	Triple protective action in IBD 1. Blocking of inflammation 2. Restoration of structure 3. Supporting of regeneration
Competitiveness	<ul style="list-style-type: none"> • By possessing the world's first original technology, there are no competitors. • Securing the position as a first-in-class biotherapeutic. • The resistin-blocking antibody exerts a triple protective mechanism of action.
Development Stage	Candidate
Route of Administration	Optimized route for clinical application

Any unauthorized distribution or reproduction of this material is strictly prohibited.